Nucleix Secures $55 Million Funding Led by RA Capital Management and Additional Prominent Life Science Investors to Advance Lung EpiCheck® for Early Detection of Lung Cancer
SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round.
Subscribe to one of our social media channels
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line “Nucleix: Please Confirm Subscription” and I sent from “firstname.lastname@example.org”.
Click the confirmation link
Click on the link inside the email and you’re good to go.